Related Experiment Video
Updated: Jun 29, 2025
00:15
Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
5.9K
Cardio-Hepatic Interaction in Cardiac Amyloidosis
Sandra Michaela Ihne-Schubert1,2,3,4, Oliver Goetze1,5,6, Felix Gerstendörfer1,2
1Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital Würzburg, 97080 Würzburg, Germany.
Journal of Clinical Medicine
|April 9, 2024
Summary
Cardiac congestion impacts liver function in cardiac amyloidosis (CA). Liver stiffness predicts mortality and reveals cardio-hepatic interactions, offering a new tool for risk stratification in CA patients.
Area of Science:
- Cardiology
- Hepatology
- Medical Diagnostics
Background:
- Cardiac amyloidosis (CA) prognosis is linked to congestion.
- The interplay between heart and liver in CA, especially liver congestion's impact, needs more research.
Purpose of the Study:
- To investigate the cardio-hepatic interaction in CA.
- To assess the prognostic value of liver affection due to cardiac congestion.
Main Methods:
- Utilized vibration-controlled transient elastography (VCTE) and 13C-methacetin breath tests for liver assessment.
- Analyzed data from 74 patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis.
Main Results:
- ATTR-CA patients exhibited reduced liver function (PDRpeak) linked to congestion.
- Liver stiffness, a marker for liver damage and congestion, predicted mortality in CA.
- Septum thickness, NT-proBNP, and PDRpeak predicted liver stiffness in both CA subtypes.
Conclusions:
- Non-invasive techniques can characterize hepatic pathophysiology in CA.
- Liver stiffness shows potential for risk stratification in cardiac amyloidosis patients.
Keywords:
13C-methacetin breath test (MBT)PDRpeakcardiac amyloidosiscongestionliver stiffnessvibration-controlled transient elastography (VTCE)More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:26Heart Failure Drugs: Inotropic Agents
577
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K